skip to main content
Language:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters

Results 1 - 20 of 84  for All Library Resources

Results 1 2 3 4 5 next page
Refined by: Database: Taylor & Francis Open Access remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice
Material Type:
Article
Add to My Research

Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice

Postgraduate medicine, 2022, Vol.134 (1), p.14-19 [Peer Reviewed Journal]

2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2021 ;ISSN: 0032-5481 ;EISSN: 1941-9260 ;DOI: 10.1080/00325481.2021.2002616

Digital Resources/Online E-Resources

2
Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis
Material Type:
Article
Add to My Research

Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis

Annals of medicine (Helsinki), 2023-12, Vol.55 (2), p.2239830-2239830 [Peer Reviewed Journal]

2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2023 ;2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2023 The Author(s) ;ISSN: 0785-3890 ;EISSN: 1365-2060 ;DOI: 10.1080/07853890.2023.2239830 ;PMID: 37498865

Full text available

3
Recent advances in the treatment of patients with obesity and chronic kidney disease
Material Type:
Article
Add to My Research

Recent advances in the treatment of patients with obesity and chronic kidney disease

Annals of medicine (Helsinki), 2023-12, Vol.55 (1), p.2203517-2203517 [Peer Reviewed Journal]

2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2023 ;2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2023 The Author(s) ;ISSN: 0785-3890 ;EISSN: 1365-2060 ;DOI: 10.1080/07853890.2023.2203517 ;PMID: 37086110

Full text available

4
Metformin use in hidradenitis suppurativa
Material Type:
Article
Add to My Research

Metformin use in hidradenitis suppurativa

The Journal of dermatological treatment, 2020-04, Vol.31 (3), p.261-263 [Peer Reviewed Journal]

ISSN: 0954-6634 ;EISSN: 1471-1753 ;DOI: 10.1080/09546634.2019.1592100

Digital Resources/Online E-Resources

5
Recent developments in adjunct therapies for type 1 diabetes
Material Type:
Article
Add to My Research

Recent developments in adjunct therapies for type 1 diabetes

Expert opinion on investigational drugs, 2022-12, Vol.31 (12), p.1311-1320 [Peer Reviewed Journal]

2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2023 ;ISSN: 1354-3784 ;EISSN: 1744-7658 ;DOI: 10.1080/13543784.2022.2159806

Digital Resources/Online E-Resources

6
Predictors of HbA1c reduction and hypoglycemia in type 2 diabetes mellitus individuals switching from premixed to basal insulin: an exploratory analysis of optimization study
Material Type:
Article
Add to My Research

Predictors of HbA1c reduction and hypoglycemia in type 2 diabetes mellitus individuals switching from premixed to basal insulin: an exploratory analysis of optimization study

Current medical research and opinion, 2022-11, Vol.38 (11), p.1807-1814 [Peer Reviewed Journal]

2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 ;ISSN: 0300-7995 ;EISSN: 1473-4877 ;DOI: 10.1080/03007995.2022.2105538

Digital Resources/Online E-Resources

7
Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy
Material Type:
Article
Add to My Research

Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy

Expert opinion on pharmacotherapy, 2023-03, Vol.24 (4), p.407-418 [Peer Reviewed Journal]

2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2023 ;ISSN: 1465-6566 ;EISSN: 1744-7666 ;DOI: 10.1080/14656566.2023.2181074

Digital Resources/Online E-Resources

8
Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM)
Material Type:
Article
Add to My Research

Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM)

Expert opinion on pharmacotherapy, 2021-02, Vol.22 (3), p.373-387 [Peer Reviewed Journal]

2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2020 ;ISSN: 1465-6566 ;EISSN: 1744-7666 ;DOI: 10.1080/14656566.2020.1817388

Digital Resources/Online E-Resources

9
Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States
Material Type:
Article
Add to My Research

Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States

Current medical research and opinion, 2022-11, Vol.38 (11), p.1785-1795 [Peer Reviewed Journal]

2022 Eli Lilly and Company. Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 ;ISSN: 0300-7995 ;EISSN: 1473-4877 ;DOI: 10.1080/03007995.2022.2085962

Digital Resources/Online E-Resources

10
Risk analysis of metformin use in prostate cancer: a national population-based study
Material Type:
Article
Add to My Research

Risk analysis of metformin use in prostate cancer: a national population-based study

The aging male, 2023-12, Vol.26 (1), p.2156497-2156497 [Peer Reviewed Journal]

2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2023 ;2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1368-5538 ;EISSN: 1473-0790 ;DOI: 10.1080/13685538.2022.2156497 ;PMID: 36974927

Full text available

11
Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus
Material Type:
Article
Add to My Research

Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus

Current medical research and opinion, 2020-04, Vol.36 (4), p.571-581 [Peer Reviewed Journal]

2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2020 ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0300-7995 ;EISSN: 1473-4877 ;DOI: 10.1080/03007995.2019.1708287

Digital Resources/Online E-Resources

12
Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance
Material Type:
Article
Add to My Research

Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance

Expert opinion on drug safety, 2021-03, Vol.20 (3), p.363-372 [Peer Reviewed Journal]

2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2020 ;ISSN: 1474-0338 ;EISSN: 1744-764X ;DOI: 10.1080/14740338.2021.1859477

Digital Resources/Online E-Resources

13
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
Material Type:
Article
Add to My Research

Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes

Vascular health and risk management, 2013-01, Vol.9 (default), p.155-163 [Peer Reviewed Journal]

2013. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2013 Ahrén, publisher and licensee Dove Medical Press Ltd 2013 ;ISSN: 1178-2048 ;ISSN: 1176-6344 ;EISSN: 1178-2048 ;DOI: 10.2147/vhrm.s33934 ;PMID: 23637538

Full text available

14
Pioglitazone and Risk of Chronic Obstructive Pulmonary Disease in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study
Material Type:
Article
Add to My Research

Pioglitazone and Risk of Chronic Obstructive Pulmonary Disease in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study

International journal of chronic obstructive pulmonary disease, 2022-01, Vol.17, p.285-295 [Peer Reviewed Journal]

2022 Tseng. ;COPYRIGHT 2022 Dove Medical Press Limited ;2022. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 Tseng. 2022 Tseng. ;ISSN: 1178-2005 ;ISSN: 1176-9106 ;EISSN: 1178-2005 ;DOI: 10.2147/COPD.S345796 ;PMID: 35177899

Full text available

15
Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations
Material Type:
Article
Add to My Research

Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations

Drug design, development and therapy, 2022-01, Vol.16, p.4449-4461 [Peer Reviewed Journal]

2022 Chao et al. ;COPYRIGHT 2023 Dove Medical Press Limited ;2022. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 Chao et al. 2022 Chao et al. ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/DDDT.S365416 ;PMID: 36601368

Full text available

16
Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis
Material Type:
Article
Add to My Research

Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis

Expert opinion on drug safety, 2021-06, Vol.20 (6), p.707-720 [Peer Reviewed Journal]

2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2021 ;ISSN: 1474-0338 ;EISSN: 1744-764X ;DOI: 10.1080/14740338.2021.1898585

Digital Resources/Online E-Resources

17
Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis
Material Type:
Article
Add to My Research

Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis

Journal of medical economics, 2020-06, Vol.23 (6), p.650-658 [Peer Reviewed Journal]

2020 Novo Nordisk A/S. Published by Informa UK Limited, trading as Taylor & Francis Group. 2020 ;ISSN: 1369-6998 ;EISSN: 1941-837X ;DOI: 10.1080/13696998.2020.1722678

Digital Resources/Online E-Resources

18
Patient-reported outcomes in elderly patients with type 2 diabetes mellitus treated with dual oral therapy: a multicenter, observational study from Italy
Material Type:
Article
Add to My Research

Patient-reported outcomes in elderly patients with type 2 diabetes mellitus treated with dual oral therapy: a multicenter, observational study from Italy

Current medical research and opinion, 2020-04, Vol.36 (4), p.555-562 [Peer Reviewed Journal]

2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2020 ;ISSN: 0300-7995 ;EISSN: 1473-4877 ;DOI: 10.1080/03007995.2019.1707649

Digital Resources/Online E-Resources

19
Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan
Material Type:
Article
Add to My Research

Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan

Expert opinion on drug safety, 2020-05, Vol.19 (5), p.625-631 [Peer Reviewed Journal]

2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2020 ;ISSN: 1474-0338 ;EISSN: 1744-764X ;DOI: 10.1080/14740338.2020.1740679

Digital Resources/Online E-Resources

20
Practical guidance for use of oral semaglutide in primary care: a narrative review
Material Type:
Article
Add to My Research

Practical guidance for use of oral semaglutide in primary care: a narrative review

Postgraduate medicine, 2020-11, Vol.132 (8), p.687-696 [Peer Reviewed Journal]

2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2020 ;ISSN: 0032-5481 ;EISSN: 1941-9260 ;DOI: 10.1080/00325481.2020.1788340

Digital Resources/Online E-Resources

Results 1 - 20 of 84  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
  1. Before 2009  (13)
  2. 2009 To 2011  (15)
  3. 2012 To 2014  (15)
  4. 2015 To 2018  (17)
  5. After 2018  (25)
  6. More options open sub menu

Searching Remote Databases, Please Wait